Dante Carrillo
Fasting and dietary protocols designed to deprive the body's cells of their primary energy source, glucose, have gained attention over the past two decades, with studies finding an association between fasting and longevity. Fasting-mimicking diets (FMDs) are low-calorie, low-sugar, low-protein, and high-fat diets that have been shown to have potent anticancer effects when combined with standard pharmacological treatments. FMDs have been found to be safe and effective in cancer treatment, resulting in biological effects in the body that may help in cancer treatment.
| Characteristics | Values |
|---|---|
| Safety | Safe for patients with cancer |
| Biological effects | Decrease of blood glucose, insulin, and growth factor, a reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration |
| Calorie restriction | Severe calorie restriction |
| Dietary intervention | Low-carbohydrate, low-protein, plant-derived diet |
| Cancer treatment | Positive clinical results in patients with breast and other cancer types |
| Cancer prevention | Effective in mouse models |
| Cancer types | Breast cancer, metastatic prostate cancer |
Explore related products
What You'll Learn
- Fasting-mimicking diets (FMD) reduce insulin growth factor (IGF-1) levels, a marker for cancer risk
- FMDs can be used in conjunction with other cancer treatments, such as chemotherapy
- FMDs are safe for cancer patients and do not cause severe weight loss
- FMDs can be used as a cancer prevention method
- FMDs can be used to target cancer cells' vulnerabilities
Fasting-mimicking diets (FMD) reduce insulin growth factor (IGF-1) levels, a marker for cancer risk
Fasting-mimicking diets (FMDs) are dietary interventions that provide low calories, low sugars, low proteins, and high fat. They are designed to starve the body's cells of glucose, their main energy source, and have gained attention as a potential cancer treatment. FMDs are typically applied for 48–72 hours in mouse studies and between 3 and 5 days in clinical studies.
FMDs have been shown to reduce insulin growth factor (IGF-1) levels, a marker for increased cancer risk. Studies have found that FMDs can reduce IGF-1, insulin, leptin, glucose, and visceral fat, all of which are risk factors for cancer. In addition, FMDs can boost normal cells' defences and enhance autophagy, the body's cellular housekeeping mechanism.
FMDs have been found to be safe and effective in boosting antitumor activity when combined with standard pharmacological treatments. In a clinical trial, 101 patients with various types of cancer underwent a five-day FMD regimen, which resulted in a decrease in blood glucose and growth factor concentration. This recapitulated the metabolic changes that mediate the anticancer effects of fasting.
FMDs can also enhance the efficacy of other cancer treatments. In mouse models, FMDs have been shown to potentiate the effects of chemo- and radiotherapy, tyrosine kinase inhibitors, immunotherapy, and hormone therapy. For example, a study found that a fasting-mimicking diet and hormone therapy induced breast cancer regression in mice. FMDs may also help to prevent cancer by causing acute or chronic reductions in IGF-1 and other risk factors.
Diet Strategies to Reduce Insulin Resistance
You may want to see also
Explore related products
FMDs can be used in conjunction with other cancer treatments, such as chemotherapy
Fasting-mimicking diets (FMDs) are emerging as effective dietary interventions with the potential to improve health and decrease the incidence of cancer and other age-related diseases. FMDs can be used in conjunction with other cancer treatments, such as chemotherapy. FMDs are more feasible than chronic dietary regimens since they allow patients to consume food regularly during the FMD cycles and maintain a regular diet, preventing severe weight loss and possible detrimental effects on glucose levels, blood pressure, and the immune system.
FMDs are low-calorie, low-sugar, low-protein, and high-fat diets that provide approximately 1,100 calories on the first day, 500–600 calories on the second, third, and fourth days, and 800–300 calories on the fifth day. FMDs have been shown to be safe and effective in cancer patients, with biological effects that may be helpful in cancer treatment. FMDs reduce blood glucose, insulin, and insulin-like growth factor 1 (IGF1) concentration, which inhibits the anabolic processes that sustain the growth and proliferation of cancer cells. FMDs also boost tumor infiltration by CD8+ T cells, the effectors of antitumor immune responses, and reduce immunosuppressive regulatory T cells.
In a clinical trial, 101 patients with various types of cancer were enrolled to undergo cyclic FMD in combination with standard-of-care antitumor therapies. The FMD cycle consisted of a five-day FMD followed by 16 to 23 days of refeeding, with the duration of the cycle depending on the schedule of concomitant antitumor treatment. The FMD was found to be safe and feasible, resulting in a consistent decrease in blood glucose and growth factor concentration, recapitulating the metabolic changes that mediate the anticancer effects of fasting/FMD. FMDs also profoundly reshape anticancer immunity by inducing the contraction of peripheral blood immunosuppressive myeloid and regulatory T-cell compartments, paralleled by enhanced intratumor Th1/cytotoxic responses and an enrichment of IFNγ.
FMDs can be effectively combined with standard pharmacological treatments, such as chemotherapy, hormone therapy, and kinase inhibitors, to enhance their anti-cancer effects while reducing side effects. In mouse models, FMDs have been shown to delay cancer growth and reduce the side effects of immunotherapy, such as cardiovascular and systemic inflammation. FMDs can also be combined with weight loss drugs, such as Ozempic, to address cancer metabolism.
Diet Dictates Future Health: Make Wise Choices
You may want to see also
Explore related products
$18.49 $35.95
FMDs are safe for cancer patients and do not cause severe weight loss
Fasting-mimicking diets (FMDs) are considered safe for cancer patients and do not cause severe weight loss. FMDs are low-calorie, low-sugar, low-protein, and high-fat diets that provide approximately 1,800 calories over five days. This type of dietary intervention has been shown to be safe and feasible for patients with cancer in several studies.
FMDs have been found to reduce blood glucose, insulin, and insulin-like growth factor 1 (IGF1) concentrations, which can inhibit the growth and proliferation of cancer cells. This reduction in blood glucose levels is a key mechanism by which FMDs target cancer cells, as cancer cells rely on glucose as their primary energy source. Additionally, FMDs have been shown to boost antitumor immunity by reducing immunosuppressive regulatory T cells and increasing effector cells, such as CD8+ T cells.
The safety and biological effects of FMDs in cancer patients have been investigated in clinical trials. In one study, 101 patients with various types of cancer underwent cyclic FMD in combination with standard antitumor therapies. The FMD cycle consisted of a five-day low-carbohydrate, low-protein, plant-derived diet, followed by a refeeding period of 16 to 23 days. The results showed that FMD was safe and resulted in a consistent decrease in blood glucose and growth factor concentration, recapitulating the metabolic changes that mediate the anticancer effects of fasting.
FMDs are also being explored as a potential cancer prevention strategy. In mouse models, FMDs have been shown to delay cancer growth and reduce the side effects associated with immunotherapy. Additionally, FMDs can prevent or reduce drug resistance acquisition, making them a potentially effective adjunct to standard cancer treatments. Unlike chronic dietary restrictions or water-only fasting, FMDs are safer and less challenging for cancer patients as they allow for regular food consumption and help prevent severe weight loss.
Butter Coffee Diet: Impact on Cholesterol Levels
You may want to see also
Explore related products
FMDs can be used as a cancer prevention method
Fasting-mimicking diets (FMDs) are emerging as effective dietary interventions with the potential to improve healthspan and decrease the incidence of cancer. FMDs are low-calorie, low-sugar, low-protein, and high-fat diets that provide minimal nutrition to the body. FMDs have been shown to be safe and effective in preclinical models and are now being studied in clinical trials in cancer patients.
Additionally, FMDs have been shown to boost the body's immune response, which can help fight cancer cells. FMDs reduce peripheral blood immunosuppressive cells and increase effector cells, both in patients with cancer and in healthy volunteers. This boost in immune cells can enhance the antitumor activity of standard cancer treatments. FMDs have also been shown to reduce the side effects of cancer treatments, such as immunotherapy-associated cardiovascular and systemic side effects.
FMDs are more feasible than chronic dietary regimens or water-only fasting because they allow patients to consume food regularly during the FMD cycles and maintain a regular diet. This prevents severe weight loss and possible detrimental effects on glucose levels, blood pressure, and the immune system. FMDs can be combined with standard cancer treatments, such as chemotherapy, immunotherapy, and hormone therapy, to enhance their effectiveness.
DASH Diet: What's in a Name?
You may want to see also
Explore related products
FMDs can be used to target cancer cells' vulnerabilities
Fasting-mimicking diets (FMDs) are emerging as effective dietary interventions with the potential to improve health and decrease the incidence of cancer and other age-related diseases. FMDs can be used to target cancer cells' vulnerabilities by exploiting their metabolic pathways and differential stress resistance.
FMDs induce changes in nutrient availability, particularly reductions in blood glucose, insulin, and growth factor concentrations. These changes affect how cancer cells adopt alternative metabolic pathways to support their growth, proliferation, and survival. By targeting these metabolic pathways, FMDs can be used to inhibit the anabolic processes that sustain cancer cells' unrestrained growth and proliferation.
Additionally, FMDs can prevent or reduce drug resistance acquisition in cancer cells. The combination of periodic FMD cycles with standard treatments has yielded positive clinical results in patients with breast cancer and other cancer types. FMDs increase protection in healthy cells while sensitizing cancer cells to various therapies. This is partly due to the generation of complex environments that promote differential stress resistance.
FMDs have been shown to boost tumor infiltration by CD8+ T cells, the effectors of antitumor immune responses, and reduce immunosuppressive regulatory T cells. This enhancement of the immune system's ability to target cancer cells is a crucial aspect of FMDs' effectiveness in targeting cancer cells' vulnerabilities.
The Italian Diet: Eating Like Italians
You may want to see also
Frequently asked questions
A fasting-mimicking diet (FMD) involves short-term, severe calorie restriction. It is a low-carbohydrate, low-protein, and high-fat diet.
FMDs reduce blood glucose, insulin, and insulin-like growth factor 1 (IGF1) concentration, which inhibits the processes that support the growth and proliferation of cancer cells. FMDs also boost the number of cells that defend against cancer cells.
FMDs have been found to be safe and potentially helpful to cancer patients. They are also more feasible than chronic dietary regimens or water-only fasting since they allow patients to consume food regularly and prevent severe weight loss.
Investigators are exploring whether dietary interventions, including FMDs, can improve outcomes and quality of life for patients with cancer. FMDs are emerging as effective dietary interventions with the potential to improve health span and decrease the incidence of cancer and other age-related diseases.
